Technology
Health
Biotechnology

Alkermes

$24.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.01 (-4.03%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Alkermes and other stocks, options, ETFs, and crypto commission-free!

About

Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. Read More The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Employees
2,300
Headquarters
Dublin, Dublin
Founded
2011
Market Cap
3.93B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
858.10K
High Today
$24.70
Low Today
$23.93
Open Price
$24.70
Volume
355.66K
52 Week High
$51.70
52 Week Low
$23.93

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Pharmaceutical
Europe (Non-UK)
Europe

News

Yahoo FinanceMay 16

ALXN or ALKS: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Alexion Pharmaceuticals (ALXN) and Alkermes (ALKS). But which of these two stocks is more attractive to value investors?

127
Yahoo FinanceMay 13

Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific Conferences

-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings -- DUBLIN, May 13, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that it will present data from its mental health portfolio at the American Psychiatric Association (APA) Annual Meeting in San Francisco and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 Conference in New Orleans; both scientific conferences will be held May 18-22, 2019. T...

27
Seeking AlphaMay 8

Alkermes Again: Best Odds Of Next 3+Month Biotech Price Gains

It followed Market-Maker Intelligence List buys to subscribers on December 17 at $31.82 (entry cost), timed out March 18 at $34.61 (+8.8% gain) under TERMD portfolio management discipline.

73

Earnings

-$0.22
-$0.03
$0.15
$0.34
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Jul 25, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.